Search Results - "Johnson, Bryon D."

Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma by Kearl, Tyce J, Jing, Weiqing, Gershan, Jill A, Johnson, Bryon D

“…Early phase clinical trials targeting the programmed death receptor-1/ligand-1 (PD-1/PD-L1) pathway to overcome tumor-mediated immunosuppression have reported…”
Get full text

PD-1 blockade after bispecific LV20.19 CAR-T modulates CAR T-cell immunophenotype without meaningful clinical response by Zurko, Joanna, Chaney, Katherine, Astle, John M, Johnson, Bryon D, Hari, Parameswaran, Shah, Nirav N

Get full text

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma by Jing, Weiqing, Gershan, Jill A, Weber, James, Tlomak, Dominique, McOlash, Laura, Sabatos-Peyton, Catherine, Johnson, Bryon D

“…Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable…”
Get full text

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria‐Targeted Atovaquone by Huang, Mofei, Xiong, Donghai, Pan, Jing, Zhang, Qi, Wang, Yian, Myers, Charles R., Johnson, Bryon D., Hardy, Micael, Kalyanaraman, Balaraman, You, Ming

“…Atovaquone, an FDA‐approved drug for malaria, is known to inhibit mitochondrial electron transport. A recently synthesized mitochondria‐targeted atovaquone…”
Get full text

Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice by Jing, Weiqing, Chen, Juan, Cai, Yuanhua, Chen, Yingyu, Schroeder, Jocelyn A., Johnson, Bryon D., Cui, Weiguo, Shi, Qizhen

“…The development of neutralizing anti-FVIII antibodies (inhibitors) is a major complication of FVIII protein replacement therapy in patients with hemophilia A…”
Get full text

Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression by AbuEid, Mahmoud, McAllister, Donna M., McOlash, Laura, Harwig, Megan Cleland, Cheng, Gang, Drouillard, Donovan, Boyle, Kathleen A., Hardy, Micael, Zielonka, Jacek, Johnson, Bryon D., Hill, R. Blake, Kalyanaraman, Balaraman, Dwinell, Michael B.

“…Metabolic heterogeneity within the tumor microenvironment promotes cancer cell growth and immune suppression. We determined the impact of mitochondria-targeted…”
Get full text

Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA by Pan, Jing, Chen, Yao, Zhang, Qi, Khatun, Achia, Palen, Katie, Xin, Gang, Wang, Li, Yang, Chuanjia, Johnson, Bryon D., Myers, Charles R., Sei, Shizuko, Shoemaker, Robert H., Lubet, Ronald A., Wang, Yian, Cui, Weiguo, You, Ming

“…Expressed on cells of the myeloid and lymphoid lineages, V-domain Ig Suppressor of T cell Activation (VISTA) is an emerging target for cancer immunotherapy…”
Get full text

Irradiation of the kidneys causes pathologic remodeling in the nontargeted heart: A role for the immune system by Lenarczyk, Marek, Laiakis, Evagelia C., Mattson, David L., Johnson, Bryon D., Kronenberg, Amy, North, Paula E., Komorowski, Richard, Mäder, Marylou, Baker, John E.

“…ABSTRACT Cardiac disease is a frequent and significant adverse event associated with radiotherapy for cancer. Identifying the underlying mechanism responsible…”
Get full text

The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation by Taylor, Mallory R., Hillard, Cecilia J., Drobyski, William R., Szabo, Aniko, Johnson, Bryon D., Zhu, Fenlu, Raison, Charles L., Cole, Steve W., Knight, Jennifer M.

“…Inflammatory physiology has been linked to behavioral and emotional symptoms in a variety of contexts and experimental paradigms. Hematopoietic cell…”
Get full text

Adoptive cell therapy using PD-1 + myeloma-reactive T cells eliminates established myeloma in mice by Jing, Weiqing, Gershan, Jill A, Blitzer, Grace C, Palen, Katie, Weber, James, McOlash, Laura, Riese, Matthew, Johnson, Bryon D

“…Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy…”
Get full text

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial by Shah, Nirav N., Johnson, Bryon D., Schneider, Dina, Zhu, Fenlu, Szabo, Aniko, Keever-Taylor, Carolyn A., Krueger, Winfried, Worden, Andrew A., Kadan, Michael J., Yim, Sharon, Cunningham, Ashley, Hamadani, Mehdi, Fenske, Timothy S., Dropulić, Boro, Orentas, Rimas, Hari, Parameswaran

“…Chimeric antigen receptor (CAR) T cells targeting CD19 are a breakthrough treatment for relapsed, refractory B cell malignancies 1 – 5 . Despite impressive…”
Get full text

Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report by Mohammed, Altaf, Dashwood, Roderick H, Dickinson, Sally, Disis, Mary L, Jaffee, Elizabeth M, Johnson, Bryon D, Khleif, Samir N, Pollak, Michael N, Schlom, Jeffrey, Shoemaker, Robert H, Stanton, Sasha E, Wondrak, Georg T, You, Ming, Zhu, Hao, Miller, Mark Steven

“…The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) convened the "Translational Advances in Cancer Prevention Agent Development (TACPAD)…”
Get full text

Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells by Cheng, Gang, Zielonka, Jacek, Ouari, Olivier, Lopez, Marcos, McAllister, Donna, Boyle, Kathleen, Barrios, Christy S, Weber, James J, Johnson, Bryon D, Hardy, Micael, Dwinell, Michael B, Kalyanaraman, Balaraman

“…Metformin (Met) is an approved antidiabetic drug currently being explored for repurposing in cancer treatment based on recent evidence of its apparent…”
Get full text

Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma by Badar, Talha, Johnson, Bryon D., Hamadani, Mehdi

Get full text

Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data by Kohler, M. Eric, Johnson, Bryon D., Palen, Katie, Chen, Qing‐Rong, Khan, Javed, Orentas, Rimas J.

“…The identification of tumor antigens remains a major objective in tumor immunology, especially in pediatric malignancies where solid tumors often do not…”
Get full text

Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? by Palen, Katie, Zurko, Joanna, Johnson, Bryon D., Hari, Parameswaran, Shah, Nirav N.

“…Chimeric antigen receptor (CAR)-modified T-cell therapy has revolutionized outcomes for patients with relapsed/refractory B-cell malignancies. Despite the…”
Get full text

Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies by Zurko, Joanna C., Xu, Huiqing, Chaney, Katherine, Schneider, Dina, Szabo, Aniko, Hari, Parameswaran, Johnson, Bryon D., Shah, Nirav N.

“…Selective immune pressure contributes to relapse due to target antigen downregulation in patients treated with anti-CD19 chimeric antigen receptor (CAR) T…”
Get full text

STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models by Jing, Weiqing, McAllister, Donna, Vonderhaar, Emily P, Palen, Katie, Riese, Matthew J, Gershan, Jill, Johnson, Bryon D, Dwinell, Michael B

“…Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates a barrier to therapy. A murine transgenic pancreatic cancer cell line…”
Get full text

Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells by Zurko, Joanna C., Fenske, Timothy S., Johnson, Bryon D., Bucklan, Daniel, Szabo, Aniko, Xu, Huiqing, Chaney, Katherine, Hamadani, Mehdi, Hari, Parameswaran, Shah, Nirav N.

“…We previously reported results of a first‐in‐human trial of bispecific LV20.19 chimeric antigen receptor T‐cell (CAR‐T) therapy, demonstrating high response…”
Get full text

CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance by ROSENBLUM, Michael D, OLASZ, Edit, WOODLIFF, Jeffery E, JOHNSON, Bryon D, KONKOL, Marja C, GERBER, Kimberly A, ORENTAS, Rimas J, SANDFORD, Gordon, TRUITT, Robert L

“…During apoptotic cell death, biochemical processes modify self-proteins and create potential autoantigens. To maintain self-tolerance in the face of natural…”
Get full text